C.M. Bidwell & Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-900
Closed -$86K – 475
2018
Q3
$86K Buy
900
+450
+100% +$43.6K 0.08% 199
2018
Q2
$43K Hold
450
– – 0.04% 254
2018
Q1
$39K Hold
450
– – 0.04% 255
2017
Q4
$38K Hold
450
– – 0.03% 259
2017
Q3
$39K Hold
450
– – 0.06% 182
2017
Q2
$35K Buy
+450
New +$31.9K 0.01% 209

Other funds holding XBI

C.M. Bidwell & Associates's XBI Position: Q4 2018 in Review

C.M. Bidwell & Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 900 shares — an estimated $86K sold.

C.M. Bidwell & Associates first reported a position in XBI in Q2 2017 and held it in 6 quarters. The position peaked at $86K in Q3 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

  • C.M. Bidwell & Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 900 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $86K.
  • C.M. Bidwell & Associates first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 6 quarters.
  • C.M. Bidwell & Associates's State Street SPDR S&P Biotech ETF position peaked at $86K in Q3 2018.
  • 427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.